Protagonist Therapeutics
PTGX
61 hedge funds and large institutions have $165M invested in Protagonist Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 16 closing their positions.
76% more capital invested
Capital invested by funds: $93.6M → $165M (+$71.3M)
0.66% more ownership
Funds ownership: 65.7% → 66.36% (+0.66%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 69 → 61 (-8)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$11.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$10.3M |
| 3 |
Millennium Management
New York
|
+$6.93M |
| 4 |
Jennison Associates
New York
|
+$3.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.23M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.36M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.57M |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$1.45M |
| 5 |
First Manhattan
New York
|
-$861K |
PTGX Hedge Fund Activity: Q3 2018 in Review
61 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2018, worth a combined $165M — up 76% from $93.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PTGX and 8 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 20 added.
The largest buyer was Farallon Capital Management, adding an estimated $11.5M. The largest seller was Great Point Partners, cutting an estimated $4.23M.
- 61 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2018, down from 69 in Q2 2018.
- Funds reported $165M of Protagonist Therapeutics stock for Q3 2018, up 76% quarter-over-quarter.
- 8 funds opened new Protagonist Therapeutics positions in Q3 2018 and 16 closed out, a net change of -8 holders.
- The largest Protagonist Therapeutics buyer in Q3 2018 was Farallon Capital Management, an estimated $11.5M added.
- The largest Protagonist Therapeutics seller in Q3 2018 was Great Point Partners, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2018.